Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of Efgartigimod PH20 SC in Adult CIDP Patients
2019-003076-39Phase 2Completed
- Sponsor
- argenx
- Start
- Feb 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of efgartigimod alfa in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by argenx. Primary endpoint: Stage A primary endpoint. Started Feb 2020; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2019-003076-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003076-39.